A transatlantic investor founded in 2001 is based in Utrecht, the Netherlands with an additional operation in Boston, United States. The firm has raised more than €1.5 million across 3 of their most recently closed funds. The firm is currently investing from its latest fund with over €600M in committed capital. The investment size ranges from €10 million up to €60 million per portfolio company over the lifetime of the investment. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.
The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm invests in all areas of life sciences, including therapeutics, medical devices, diagnostics and digital health companies. In the past, the firm did not look at therapeutics, but is now actively investing in therapeutics companies as well. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.
The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply